AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04412694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preoparative blood laboratory tests
Description: Preoperative parameters such as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronin will be measured in serum.
Study NCT04412694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative laboratory blood tests at 6 hour
Description: At 6 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium will be measured in serum.
Study NCT04412694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Postoperative laboratory blood tests at 6 hour
Description: At 6 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium will be measured in serum.
Study NCT04412694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative laboratory blood tests at 24 hour
Description: At 24 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10 will be measured in serum.
Study NCT04412694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Postoperative laboratory blood tests at 24 hour
Description: At 24 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10 will be measured in serum.
Study NCT04412694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative laboratory drainage fluid tests at 24 hour
Description: At 24 hour after surgery such parameters as interleukin 1β, interleukin 6, interleukin 10 will be measured in drainage fluid.
Study NCT04412694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Postoperative laboratory drainage fluid tests at 24 hour
Description: At 24 hour after surgery such parameters as interleukin 1β, interleukin 6, interleukin 10 will be measured in drainage fluid.
Study NCT04412694 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Total thyroidectomy
Description: Patients will undergo total thyroidectomy under general anesthesia.
Study NCT04412694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Description: Patients will undergo total thyroidectomy under general anesthesia.
Study NCT00654056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actrapid (human insulin)
Description: On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
Study NCT02865278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard meal
Description: The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
Study NCT02865278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard meal
Description: The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
Study NCT01920516 — intervention group
Intervention type: DRUG
Intervention: Melphalan
Description: Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Symptomatic hypocalcaemia at 6 hour
Description: At 6 hour after surgery patients will be assessed for signs of hypocalcaemia.
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptomatic hypocalcaemia at 6 hour
Description: At 6 hour after surgery patients will be assessed for signs of hypocalcaemia.
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Symptomatic hypocalcaemia at 24 hour
Description: At 24 hour after surgery patients will be assessed for signs of hypocalcaemia.
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptomatic hypocalcaemia at 24 hour
Description: At 24 hour after surgery patients will be assessed for signs of hypocalcaemia.
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative pain at 6 hour
Description: At 6 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative pain at 6 hour
Description: At 6 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative pain at 24 hour
Description: At 24 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative pain at 24 hour
Description: At 24 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative nausea and vomiting at 6 hour
Description: At 6 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative nausea and vomiting at 6 hour
Description: At 6 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative nausea and vomiting at 24 hour
Description: At 24 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative nausea and vomiting at 24 hour
Description: At 24 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative sore throat and hoarseness at 6 hour
Description: At 6 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative sore throat and hoarseness at 6 hour
Description: At 6 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
Study NCT04412694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative sore throat and hoarseness at 24 hour
Description: At 24 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
Study NCT00180167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: randomization between two established Chemotherapies
Study NCT00180167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: randomization between two established Chemotherapies
Study NCT01537146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Bolus infusion via catheter/6H for 24H
Study NCT01537146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
Study NCT01708447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L.M.X.4.® cream
Description: A lidocaine topical anesthetic cream
Study NCT01708447 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: A placebo cream
Description: Placebo cream containing no anesthetic properties.
Study NCT01708447 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT01708447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT01951703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Control, senfilcon A
Study NCT01951703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: Test, senofilcon A
Study NCT00005799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00005799 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo low-dose TBI
Study NCT00005799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo nonmyeloablative HSCT
Study NCT00005799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo nonmyeloablative allogeneic bone marrow transplantation
Study NCT00005799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplantation
Study NCT00005799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Undergo DLI
Study NCT00005799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO
Study NCT00005799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study NCT00005799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00005799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01157195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-AutoCITE
Description: Automated, remotely-administered form of CI therapy
Study NCT01157195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CI therapy
Description: CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
Study NCT01566461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Description: Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
Study NCT01566461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA Balloon: Balloon Angioplasty
Description: Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
Study NCT00704561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)
Description: ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
Study NCT00955942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: Given orally
Study NCT02832128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUT00063
Description: 4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
Study NCT00704561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)
Description: DRIVER bare metal stent implanted in acute myocardial infarction
Study NCT00704561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stent implantation
Description: Comparison of Drug Eluting versus Bare Metal Stent
Study NCT00704561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Coronary Stent
Description: Comaprison between Drug Eluting and Bare Metal Coronary Stents
Study NCT02832128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 capsules of placebo, to take orally with food for 4 weeks
Study NCT00955942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01428453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250mg rilapladib
Description: Experimental Drug
Study NCT01428453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator
Study NCT01996709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide-based contact lens solution
Study NCT01996709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual contact lens solution
Description: Biguanide-preserved
Study NCT02610491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin
Description: Citrus peel extract
Study NCT02610491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose
Study NCT01730404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001 DPI
Study NCT01996709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual contact lenses
Description: Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
Study NCT01996709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual contact lenses
Description: Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
Study NCT02442960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herbal treatment (SA100)
Description: This treatment has been used extensively in traditional medicine practices for hundreds of years.
Study NCT01817933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical therapy
Study NCT01641692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 Active treatment or Placebo
Description: Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
Study NCT01730404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Study NCT01641692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719 Active treatment or Placebo
Description: Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
Study NCT01641692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GSK573719 (Sub-group cohort)
Description: Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
Study NCT01730404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01641692 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719 (Sub-group cohort)
Description: Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
Study NCT06437626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexidol
Description: 50 mg/ml IV solution, 250 mg tablets
Study NCT06437626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV solution, Placebo tablets
Study NCT01641692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol/Albuterol
Description: Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
Study NCT04536948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooling Gel
Description: Cooling gel (Nelsons Arnicare Arnica Cooling Gel) was applied to the lateral epicondyle region with sponge head 3 times a day. The cooling gel was applied to the painful area around the lateral epicondyle
Study NCT04536948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pack
Description: Cold pack was applied to the painful area for 15 minutes on a moist towel placed on the painful area around the lateral epicondyle.
Study NCT00859339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine ( 1000 mg/m2) IV days 1 and 8
Study NCT01641692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol/Albuterol
Description: Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
Study NCT00859339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (70 mg/m2) IV day 1
Study NCT01487954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alkaline water
Description: Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
Study NCT01487954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: distilled water
Description: Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.
Study NCT00859339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Sunitinib malate (37.5 mg) oral daily for days 1-14
Study NCT00859339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
Study NCT00750529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine and Donepezil
Description: the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
Study NCT04234087 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Additional balance and resistance training
Description: Additional exercise program with balance and resistance training three times per week. After completion participants are encouraged to continue exercise training at home according to recommendations and will receive control calls every two weeks.
Study NCT02387736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy-6 months
Description: Modification of behaviours achieved with reframing thoughts and impulses
Study NCT02387736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical Behaviour Therapy-12 months
Description: Modification of behaviours achieved with reframing thoughts and impulses
Study NCT01909882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Massage therapy
Description: One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.